Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITA AUTÒNOMA DE BARCELONA currently has 2 pending office actions in the Biotechnology & Pharmaceuticals sector. These actions are assigned to 2 distinct examiners and 2 distinct art units, representing a diversified prosecution environment. This structure suggests that the university's current research output is being examined across multiple technical niches within the pharmaceutical field.
NICOL, ALEXANDER W is the busiest examiner for the portfolio, with 1 pending office action under review. Given that the total pending office actions count is 2, the busiest examiner pending count of 1 indicates that each of the 2 distinct examiners is responsible for one case. This balance ensures that the prosecution progress is not tied to a single examiner's backlog. For practitioners, this requires a versatile strategy to address the unique requirements of 2 distinct art units and their respective examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
| POPA, ILEANA | 1 | 21.4% | +15.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 22d |
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17614390 | Insulin gene therapy | NICOL, ALEXANDER W | 1634 | §103§112 | Non-Final OA | — | Pending | Nov 26, 2021 |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | POPA, ILEANA | 1633 | §103 | Final Rejection | 22d | Pending | Mar 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial